Ramos, Teresa LopesGarcía-Guerrero, EstefaníaCaballero-Velázquez, TeresaRodríguez-Gil, AlfonsoCaracuel-García, RocíoNufer, MelanieRobles-Frías, María JoséBarbado, María VictoriaPérez-Simón, José A2025-01-072025-01-072021-09-23https://hdl.handle.net/10668/27863In this study, we aimed to modify the immune response in the long term after allogeneic bone marrow transplantation (allo-BMT) by using the proteasome inhibitor ixazomib (IXZ) at the late stages of the post-transplant period. This approach facilitated the immune reconstitution after transplantation. IXZ significantly prolonged survival and decreased the risk of chronic graft-versus-host disease (cGvHD) in two different murine models without hampering the graft-versus-leukemia (GvL) effect, as confirmed by bioluminescence assays. Remarkably, the use of IXZ was related to an increase of regulatory T cells both in peripheral blood and in the GvHD target organs and a decrease of effector donor T cells. Regarding B cells, IXZ treated mice had faster recovery of B cells in PB and of pre-pro-B cells in the bone marrow. Mice receiving ixazomib had a lower number of neutrophils in the GvHD target organs as compared to the vehicle group. In summary, delayed administration of IXZ ameliorated cGvHD while preserving GvL and promoted a pro-tolerogenic immune response after allo-BMT.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AnimalsBone Marrow TransplantationBoron CompoundsGlycineGraft vs Host DiseaseGraft vs Leukemia EffectImmunityMiceresearch article34556806open access10.1038/s41409-021-01452-11476-5365PMC8636253https://www.nature.com/articles/s41409-021-01452-1.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8636253/pdf